NORTHBROOK, Ill., July 18, 2016 /PRNewswire/ -- Astellas today announced that John Demaree has been promoted to vice president, Oncology Marketing, Astellas Americas. In this role, Demaree will lead Astellas' oncology marketing team in promotion of in-market products, preparation for new oncology product launches and strategic planning and collaboration with the company's partner organizations in the Americas region. He will report to Mark Reisenauer, senior vice president, Oncology Business Unit, Astellas Americas.
"Astellas is committed to making a difference in the lives of cancer patients through an emphasis on innovation and R&D," said Reisenauer. "We are confident that John's commercial experience in oncology will help us make strides in improving care for the patients we serve."
Demaree has over 25 years of experience working in the pharmaceutical industry, with over 20 years in oncology. Prior to his promotion, Demaree served as executive director, Oncology Marketing, where he helped execute the launch of XTANDI and promotion of Tarceva. Before joining Astellas, he worked at Abbott as the general manager for oncology business development and alliance management. Demaree also held roles of increasing responsibility at Novartis and Eli Lilly and Company.
Demaree holds a bachelor's in marketing and a master's in marketing and finance from Indiana University.
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.